In this video, Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, briefly summarizes the role of chemoimmunotherapy in Waldenström’s macroglobulinemia (WM) in the era of novel targeted agents, and highlights the importance of combination approaches. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Consulting fees or research funds from Abbvie, AstraZeneca, BeiGene, Casma, Cellectar, Janssen, Pharmcyclics, Roche, TG Therapeutics.